GT Biopharma Inc

Stock Chart, Company Information, and Scan Results

$0.76(as of Dec 19, 3:57 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

GT Biopharma Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$0.76
Ticker SymbolGTBP
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees1
CountyUSA
Market Cap$7.4M

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

GT Biopharma Inc In Our Stock Scanner

As of Dec 19, 2025
example chart graphic
Scan Name: WedgeScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.